Breaking News

Financial Report: Akorn

February 26, 2013

Achieves record 4Q and FY revenue


4Q Revenues: $71.5 million (+68%)

4Q Earnings: $8.8 million  (+54%)

FY Revenues: $256.2 million (+87%)

FY Earnings: $35.4 million (-18%)

Comments: Growth in the quarter and FY was driven by the Lundbeck and Kilitch acquisitions, the sale of newly approved and re-launched products, and growth of established products, offset by decreases in the U.S. contract services business.
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors